SynthesisBioMed research international2017
Effect of Calcium Channel Blockers on Lower Urinary Tract Symptoms: A Systematic Review.
Synthesis in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Ion Channels as Therapeutic Targets in Overactive Bladder: A Narrative Review of Mechanisms, Translational Evidence, and Current Gaps.Lower urinary tract symptoms · 2026Review
- Sacubitril/valsartan improves nocturia in hypertensive patients: a pilot study.Translational andrology and urology · 2026Article
- Model of Nocturnal Polyuria in Older Japanese Adults Receiving Enteral Nutrition in Medical Long-Term Care Hospitals: An Exploratory Cross-Sectional Study.Lower urinary tract symptoms · 2026Observational
- Orai storeoperated CaChannels (Austin, Tex.) · 2025Review
- Role of local angiotensin II signaling in bladder function.American journal of physiology. Renal physiology · 2024Review
- Insights into the associative role of hypertension and angiotensin II receptor in lower urinary tract dysfunction.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Lower Urinary Tract Disorders as Adverse Drug Reactions-A Literature Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Pharmacist-driven interventions to de-escalate urinary antimuscarinics in the Programs of All-Inclusive Care for the Elderly.Journal of the American Geriatrics Society · 2022Observational
- Calcium Channel Blockers Are Associated with Nocturia in Men Aged 40 Years or Older.Journal of clinical medicine · 2021Article
- Sarcopenia and Visceral Obesity are Significantly Related to Severe Storage Symptoms in Geriatric Female Patients.Research and reports in urology · 2021Article
- Nocturia as an Unrecognized Symptom of Uncontrolled Hypertension in Black Men Aged 35 to 49 Years.Journal of the American Heart Association · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous medications are known to be associated with the development of lower urinary tract symptoms (LUTS). One such medication group is calcium channel blockers (CCB).
objectiveTo critically examine the literature regarding the involvement of CCB in manifestation of LUTS in humans.
methodsA systematic literature search was conducted on PubMed, SciELO, Scopus, and OpenGrey databases to find all potentially relevant research studies before August 2016.
resultsFive studies met the inclusion criteria and were included in this review. Three out of five studies stated that CCB were involved in either precipitation or exacerbation of LUTS. As for the remaining two studies, one study found out that only the monotherapy of CCB was associated with increased prevalence of nocturia and voiding symptoms in young females, whereas the other study reported an inverse association of CCB with LUTS. The methodological quality of studies was considered high for four studies and low for one study.
conclusionHealthcare providers should make efforts for an earlier identification of the individuals at risk of LUTS prior to the commencement of CCB therapy. Moreover, patients should be counselled to notify their healthcare provider if they notice urinary symptoms after the initiation of CCB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.